Hall De Shon, Roberts Edda M, Ferguson Sharon, Wang Zhuangzhi, Davies Joanna D
Department of Immunology, IMM-23, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
J Clin Immunol. 2003 May;23(3):162-74. doi: 10.1023/a:1023353711132.
Late allograft rejection due to transplant vasculopathy continues to be a major clinical problem. Increasing the ratio of donor transplant size to recipient weight has been shown to reduce the incidence of late allograft failure. Using a murine pancreas transplant model we have tested the hypothesis that increasing the donor transplant size in a recipient can promote long-term allograft survival by promoting recovery from transplant vasculopathy. Recipients of an allograft that showed extensive vasculopathy were transplanted with a second donor transplant. The effect of the second allograft on the vasculopathy present in the first graft was measured. Transplanting a second allograft reversed all signs of ongoing rejection, including transplant vasculopathy, resulting in long-term survival of the first graft. Vasculopathy was only reversed if the first and second grafts were from the same mouse strain, suggesting an antigen-specific mechanism. However, the recovery of the first graft was not associated with antigen-specific peripheral tolerance.
由移植血管病变导致的晚期移植物排斥仍然是一个主要的临床问题。已表明增加供体移植物大小与受体体重的比例可降低晚期移植物失败的发生率。使用小鼠胰腺移植模型,我们检验了这样一个假说:在受体中增加供体移植物大小可通过促进移植血管病变的恢复来促进移植物的长期存活。对显示广泛血管病变的同种异体移植物受体进行第二次供体移植物移植。测量了第二次同种异体移植物对第一个移植物中存在的血管病变的影响。移植第二个同种异体移植物逆转了正在进行的排斥反应的所有迹象,包括移植血管病变,从而使第一个移植物长期存活。只有当第一个和第二个移植物来自同一小鼠品系时,血管病变才会逆转,这表明存在一种抗原特异性机制。然而,第一个移植物的恢复与抗原特异性外周耐受无关。